Bedrocan International, a producer of pharmaceutical-grade medicinal cannabis, is set to make a return to the Canadian market, reaffirming its long-held commitment to providing standardized medicinal cannabis for patients. The company recently acquired a facility in Scarborough, a strategic location that once served as its operational base in Canada, and has been granted a new cultivation license by Health Canada. Production is expected to begin in early 2025, marking Bedrocan's renewed presence in Canada after several years of absence.

"We have had a strictly pharmaceutical approach since our foundation in 2003. We use the knowledge we have acquired in more than twenty years of business to produce cannabis products that benefit patients exclusively," said Bedrocan's CEO Jaap Erkelens. Bedrocan's meticulous approach to production ensures consistent levels of THC and CBD in all of its products, offering patients a reliable, standardized therapeutic experience. This level of precision is critical for both patients and prescribing physicians who seek consistent outcomes from medical cannabis treatments.

In its return to the Canadian market, Bedrocan aims to introduce several of its standardized cannabis products, with the Bedrocan brand at the forefront. The company plans to distribute these products via a third party through the medical sales channel, providing registered patients with direct access to high-quality, medicinal cannabis.

The company's return follows a previous venture in Canada that ended with the termination of its partnership with Canopy Growth Corp (NASDAQ:CGC). Despite this setback, Bedrocan remained steadfast in its desire to return to the Canadian market. "We are thrilled to be coming back to Canada," Erkelens said. "We look forward to serving patients in Canada and positively impacting the Canadian healthcare landscape."

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Cover image made with AI